Description: Ocular Therapeutix, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of therapies based on its proprietary hydrogel platform technology for treating eye diseases and conditions. The company offers ReSure Sealant, a topical liquid hydrogel that creates a sealant to prevent post-surgical leakage from clear corneal incisions made during cataract surgery Its lead product candidates comprise OTX-DP, which is in Phase III clinical trials for the treatment of post-surgical ocular inflammation and pain; and OTX-TP that is in Phase II clinical trials for the treatment of glaucoma and ocular hypertension. The company's earlier stage product candidates include OTX-DP, which is in Phase II clinical trials for the treatment of allergic conjunctivitis; OTX-MP that has completed Phase I clinical trials for the treatment of bacterial conjunctivitis; and Anti-VEGF hydrogel depot, which is in preclinical testing for the treatment of wet AMD. Ocular Therapeutix, Inc. sells its ReSure Sealant through a network of independent medical device distributors in the United States. The company was founded in 2006 and is headquartered in Bedford, Massachusetts.
Home Page: www.ocutx.com
OCUL Technical Analysis
24 Crosby Drive
Bedford,
MA
01730
United States
Phone:
781 357 4000
Officers
Name | Title |
---|---|
Mr. Antony Mattessich | Pres, CEO & Director |
Mr. Donald Notman Jr. | Chief Financial Officer |
Dr. Peter K. Jarrett Ph.D. | Chief Scientific Officer |
Mr. Philip C. Strassburger | Gen. Counsel |
Mr. William H. Ransone II | VP of Global Sales & Marketing |
Ms. Tracy Smith | VP of HR |
Mr. Scott Corning | Sr. VP of Commercial |
Mr. Christopher G. White | Chief Bus. Officer |
Dr. Rabia Gurses Ozden M.D. | Chief Medical Officer |
Dr. Karen-Leigh Edwards M.B.A., Ph.D. | Sr. VP of Technical Operations |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Pharmaceuticals |
GIC Sub-Industry: | Pharmaceuticals |
Forward PE: | 0 |
---|---|
Trailing PE: | 0 |
Price-to-Book MRQ: | 4.8976 |
Price-to-Sales TTM: | 4.1736 |
IPO Date: | 2014-07-25 |
Fiscal Year End: | December |
Full Time Employees: | 228 |